Adams Asset Advisors LLC Has $9.01 Million Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Adams Asset Advisors LLC lowered its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 9.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 147,767 shares of the biopharmaceutical company's stock after selling 15,440 shares during the quarter. Bristol Myers Squibb comprises approximately 1.2% of Adams Asset Advisors LLC's investment portfolio, making the stock its 26th biggest holding. Adams Asset Advisors LLC's holdings in Bristol Myers Squibb were worth $9,012,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Pinney & Scofield Inc. bought a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC bought a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $26,000. Global Wealth Strategies & Associates lifted its stake in Bristol Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 275 shares in the last quarter. Transce3nd LLC bought a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $28,000. Finally, Fairway Wealth LLC bought a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $28,000. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY traded up $0.03 on Friday, hitting $46.87. The company had a trading volume of 47,283,703 shares, compared to its average volume of 13,081,192. Bristol Myers Squibb Company has a 1-year low of $39.35 and a 1-year high of $63.33. The stock has a market cap of $95.38 billion, a price-to-earnings ratio of 17.55, a P/E/G ratio of 1.39 and a beta of 0.38. The stock has a 50 day moving average price of $48.20 and a 200 day moving average price of $54.35. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The firm had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same period in the previous year, the company earned ($4.40) earnings per share. The company's quarterly revenue was down 5.6% on a year-over-year basis. Analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be issued a $0.62 dividend. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.29%. Bristol Myers Squibb's dividend payout ratio is currently 92.88%.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of Bristol Myers Squibb stock in a transaction dated Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.09% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BMY. UBS Group lowered their price objective on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Jefferies Financial Group lowered their price objective on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Bristol Myers Squibb presently has a consensus rating of "Hold" and a consensus price target of $58.00.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.